Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | EIF4EBP1 | Q13541 | 2/20 | 0.38 |
| ▸ | FASN | P49327 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenol SCHEMBL18587635 | 0.94 | EGFR (0.41) | XDHSCN9AEGFRMRGPRX4PTGDR2 | |
| SCHEMBL18587923 | 0.89 | CECR2 (0.43) | XDHEGFRMRGPRX4PTGDR2EIF4EBP1 | |
| SCHEMBL18587810 | 0.84 | MAPT (0.45) | XDHEGFRMRGPRX4EIF4EBP1 | |
| SCHEMBL18587807 | 0.84 | MAPT (0.45) | XDHEGFRMRGPRX4EIF4EBP1 | |
| SCHEMBL18587267 | 0.83 | RAB9A (0.48) | — | |
| SCHEMBL18587789 | 0.80 | CTSS (0.43) | SCN9ACTSSCTSKMAOAMAOB | |
| SCHEMBL18587287 | 0.78 | MRGPRX4 (0.49) | MRGPRX4EIF4EBP1FASN | |
| SCHEMBL18587212 | 0.77 | MAPT (0.47) | SCN9AMRGPRX4FASN | |
| SCHEMBL18587839 | 0.76 | SCN9A (0.36) | XDHSCN9AEGFRERBB2FASN | |
| SCHEMBL18587284 | 0.75 | KAT6A (0.43) | SCN9AFASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352330-B2 | Phenoxymethyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11352330-B2 | Phenoxymethyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20200339522-A1 | PHENOXYMETHYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-20200339522-A1 | PHENOXYMETHYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-29 | — | — | US | disclosed |
| EP-3344619-B1 | PHENOXYMETHYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-10-28 | — | — | EP | disclosed |
| EP-3344619-B1 | PHENOXYMETHYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-10-28 | — | — | EP | disclosed |
| US-10640472-B2 | Phenoxymethyl derivatives | HOFFMAN-LA ROCHE INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-10640472-B2 | Phenoxymethyl derivatives | HOFFMAN-LA ROCHE INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20180201588-A1 | PHENOXYMETHYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180201588-A1 | PHENOXYMETHYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180201588-A1 | PHENOXYMETHYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-07-19 | — | — | US | disclosed |
| EP-3344619-A1 | PHENOXYMETHYL DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2018-07-11 | — | — | EP | disclosed |
| WO-2017037146-A1 | PHENOXYMETHYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-03-09 | — | — | WO | disclosed |
| WO-2017037146-A1 | PHENOXYMETHYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339522-A1 | PHENOXYMETHYL DERIVATIVES | CNKSR1, RB1, RCOR1 | XDH 4008/4885SCN9A 4486/4885EGFR 1976/4885 |
| US-10640472-B2 | Phenoxymethyl derivatives | CNKSR1, RB1, RCOR1 | XDH 4008/4885SCN9A 4486/4885EGFR 1976/4885 |
| US-20180201588-A1 | PHENOXYMETHYL DERIVATIVES | CNKSR1, RB1, RCOR1 | XDH 4008/4885SCN9A 4486/4885EGFR 1976/4885 |
| US-11352330-B2 | Phenoxymethyl derivatives | CNKSR1, RB1, RCOR1 | XDH 4008/4885SCN9A 4486/4885EGFR 1976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.